145 related articles for article (PubMed ID: 24308627)
1. Design, synthesis, and biological activity of novel dicoumarol glucagon-like peptide 1 conjugates.
Han J; Sun L; Chu Y; Li Z; Huang D; Zhu X; Qian H; Huang W
J Med Chem; 2013 Dec; 56(24):9955-68. PubMed ID: 24308627
[TBL] [Abstract][Full Text] [Related]
2. Novel coumarin modified GLP-1 derivatives with enhanced plasma stability and prolonged in vivo glucose-lowering ability.
Han J; Sun L; Huang X; Li Z; Zhang C; Qian H; Huang W
Br J Pharmacol; 2014 Dec; 171(23):5252-64. PubMed ID: 25039358
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and Evaluation of a Series of Long-Acting Glucagon-Like Peptide-1 (GLP-1) Pentasaccharide Conjugates for the Treatment of Type 2 Diabetes.
Irwin N; Patterson S; de Kort M; Moffett RC; Wisse JA; Dokter WH; Bos ES; Miltenburg AM; Flatt PR
ChemMedChem; 2015 Aug; 10(8):1424-34. PubMed ID: 26059252
[TBL] [Abstract][Full Text] [Related]
4. Lithocholic Acid-Based Peptide Delivery System for an Enhanced Pharmacological and Pharmacokinetic Profile of Xenopus GLP-1 Analogs.
Han J; Chen X; Zhao L; Fu J; Sun L; Zhang Y; Zhou F; Fei Y
Mol Pharm; 2018 Jul; 15(7):2840-2856. PubMed ID: 29799205
[TBL] [Abstract][Full Text] [Related]
5. Site-specific fatty chain-modified exenatide analogs with balanced glucoregulatory activity and prolonged in vivo activity.
Sun L; Huang X; Han J; Cai X; Dai Y; Chu Y; Wang C; Huang W; Qian H
Biochem Pharmacol; 2016 Jun; 110-111():80-91. PubMed ID: 27155328
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological characterization and antidiabetic activity of a long-acting glucagon-like peptide-1 analogue conjugated to an antithrombin III-binding pentasaccharide.
Patterson S; de Kort M; Irwin N; Moffett RC; Dokter WH; Bos ES; Miltenburg AM; Flatt PR
Diabetes Obes Metab; 2015 Aug; 17(8):760-70. PubMed ID: 25929155
[TBL] [Abstract][Full Text] [Related]
7. Rational design of dimeric lipidated Xenopus glucagon-like peptide 1 analogues as long-acting antihyperglycaemic agents.
Han J; Huang Y; Chen X; Zhou F; Fei Y; Fu J
Eur J Med Chem; 2018 Sep; 157():177-187. PubMed ID: 30096651
[TBL] [Abstract][Full Text] [Related]
8. Biological activity studies of the novel glucagon-like peptide-1 derivative HJ07.
Han J; Sun LD; Qian H; Huang WL
Chin J Nat Med; 2014 Aug; 12(8):613-8. PubMed ID: 25156287
[TBL] [Abstract][Full Text] [Related]
9. Novel peptidic dual GLP-1/glucagon receptor agonist alleviates diabetes and diabetic complications in combination with low-intensity ultrasound.
Ding WX; Wang HY; Peng LJ; Zhang F; Yuan S; Zhao LH
Eur Rev Med Pharmacol Sci; 2020 Dec; 24(23):12423-12436. PubMed ID: 33336763
[TBL] [Abstract][Full Text] [Related]
10. Design and characterization of novel oxyntomodulin derivatives with potent dual GLP-1/glucagon receptor activation and prolonged antidiabetic effects.
Pei Z; Zhou D; Yan J; Wang S; Yang X; Pei Z
Life Sci; 2020 Jul; 253():117651. PubMed ID: 32304764
[TBL] [Abstract][Full Text] [Related]
11. Novel fatty chain-modified glucagon-like peptide-1 conjugates with enhanced stability and prolonged in vivo activity.
Han J; Huang X; Sun L; Li Z; Qian H; Huang W
Biochem Pharmacol; 2013 Jul; 86(2):297-308. PubMed ID: 23707756
[TBL] [Abstract][Full Text] [Related]
12. Xenopus GLP-1-inspired discovery of novel GLP-1 receptor agonists as long-acting hypoglycemic and insulinotropic agents with significant therapeutic potential.
Han J; Chen X; Wang Y; Fei Y; Zhou F; Zhang Y; Liu L; Si P; Fu J
Biochem Pharmacol; 2017 Oct; 142():155-167. PubMed ID: 28668697
[TBL] [Abstract][Full Text] [Related]
13. Development and characterization of a glucagon-like peptide 1-albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo.
Kim JG; Baggio LL; Bridon DP; Castaigne JP; Robitaille MF; Jetté L; Benquet C; Drucker DJ
Diabetes; 2003 Mar; 52(3):751-9. PubMed ID: 12606517
[TBL] [Abstract][Full Text] [Related]
14. Rational design and biological evaluation of gemfibrozil modified Xenopus GLP-1 derivatives as long-acting hypoglycemic agents.
Han J; Fu J; Yang Q; Zhou F; Chen X; Li C; Yin J
Eur J Med Chem; 2020 Jul; 198():112389. PubMed ID: 32388115
[TBL] [Abstract][Full Text] [Related]
15. A novel GLP-1 analog exhibits potent utility in the treatment of type 2 diabetes with an extended half-life and efficient glucose clearance in vivo.
Li Y; Xu W; Tang L; Gong M; Zhang J
Peptides; 2011 Jul; 32(7):1408-14. PubMed ID: 21664938
[TBL] [Abstract][Full Text] [Related]
16. Long-acting GLP-1 analogue in V-shaped conformation by terminal polylysine modifications.
Yang X; Li Y; Wang Y; Zheng X; Kong W; Meng F; Zhou Z; Liu C; Li Y; Gong M
Mol Pharm; 2014 Nov; 11(11):4092-9. PubMed ID: 25243635
[TBL] [Abstract][Full Text] [Related]
17. A new orally available glucagon-like peptide-1 receptor agonist, biotinylated exendin-4, displays improved hypoglycemic effects in db/db mice.
Jin CH; Chae SY; Son S; Kim TH; Um KA; Youn YS; Lee S; Lee KC
J Control Release; 2009 Feb; 133(3):172-7. PubMed ID: 18977255
[TBL] [Abstract][Full Text] [Related]
18. S3-2, a novel long-lasting oxyntomodulin derivative, exerts improvement on diabesity and renal injury through activating GLP-1 and glucagon receptors.
Huang P; Meng L; Tan J; Gu X; Huang M; Huang F; Ma R; Wang J
Life Sci; 2021 Apr; 270():119136. PubMed ID: 33508289
[TBL] [Abstract][Full Text] [Related]
19. Design, screening and biological evaluation of novel fatty acid chain-modified oxyntomodulin-based derivatives with prolonged glucose-lowering ability and potent anti-obesity effects.
Zhao L; Wang B; Wang L; Zhao X; Chen Z; Sun L
Org Biomol Chem; 2019 Sep; 17(33):7760-7771. PubMed ID: 31389463
[TBL] [Abstract][Full Text] [Related]
20. An overview of once-weekly glucagon-like peptide-1 receptor agonists--available efficacy and safety data and perspectives for the future.
Madsbad S; Kielgast U; Asmar M; Deacon CF; Torekov SS; Holst JJ
Diabetes Obes Metab; 2011 May; 13(5):394-407. PubMed ID: 21208359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]